NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Moderate Buy” by Analysts

NeoGenomics, Inc. (NASDAQ:NEOGet Free Report) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $18.64.

Several equities analysts have weighed in on the company. BTIG Research dropped their price objective on NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a report on Friday, December 29th. Morgan Stanley increased their price objective on NeoGenomics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. The Goldman Sachs Group reduced their price objective on NeoGenomics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Friday, October 20th. Piper Sandler cut their price target on NeoGenomics from $23.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, October 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $21.00 price target on shares of NeoGenomics in a research report on Thursday, December 28th.

Read Our Latest Stock Analysis on NEO

Insider Transactions at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 2,669 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $18.39, for a total value of $49,082.91. Following the completion of the transaction, the general counsel now directly owns 37,140 shares in the company, valued at approximately $683,004.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas increased its position in shares of NeoGenomics by 6.0% during the second quarter. Teacher Retirement System of Texas now owns 28,664 shares of the medical research company’s stock worth $461,000 after acquiring an additional 1,621 shares during the period. Mach 1 Financial Group LLC acquired a new stake in shares of NeoGenomics in the second quarter valued at about $491,000. SG Americas Securities LLC acquired a new position in NeoGenomics during the third quarter worth about $1,844,000. Brown Advisory Inc. boosted its holdings in NeoGenomics by 25.0% in the 3rd quarter. Brown Advisory Inc. now owns 8,246,202 shares of the medical research company’s stock valued at $101,428,000 after purchasing an additional 1,651,717 shares during the last quarter. Finally, Emerald Advisers LLC boosted its holdings in NeoGenomics by 16.4% in the 3rd quarter. Emerald Advisers LLC now owns 1,927,074 shares of the medical research company’s stock valued at $23,703,000 after purchasing an additional 270,855 shares during the last quarter. Institutional investors own 91.36% of the company’s stock.

NeoGenomics Stock Up 3.2 %

NASDAQ:NEO opened at $14.50 on Friday. The stock has a 50-day simple moving average of $17.02 and a 200 day simple moving average of $15.54. NeoGenomics has a 52-week low of $11.03 and a 52-week high of $21.22. The company has a debt-to-equity ratio of 0.57, a quick ratio of 6.06 and a current ratio of 6.32. The company has a market cap of $1.85 billion, a PE ratio of -18.83 and a beta of 1.12.

NeoGenomics (NASDAQ:NEOGet Free Report) last released its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. The company had revenue of $151.95 million during the quarter, compared to analysts’ expectations of $142.15 million. NeoGenomics had a negative return on equity of 4.95% and a negative net margin of 16.76%. On average, sell-side analysts expect that NeoGenomics will post -0.36 EPS for the current fiscal year.

NeoGenomics Company Profile

(Get Free Report

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

See Also

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.